EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of active ulcerative colitis with a recombinant humanised antibody to alpha-4 integrin



Treatment of active ulcerative colitis with a recombinant humanised antibody to alpha-4 integrin



Gut 44(SUPPL 1): A36, April




(PDF 0-2 workdays service: $29.90)

Accession: 035980734

Download citation: RISBibTeXText



Related references

A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Alimentary Pharmacology & Therapeutics 16(4): 699-705, April, 2002

Randomised double-blind placebo-controlled trial of recombinant humanised antibody to alpha-4 integrin in active Crohns disease. Gut 44(SUPPL 1): A42, April, 1999

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut 55(11): 1568-1574, 2006

Anti-TNF-alpha antibody treatment of patients with active ulcerative colitis. Ugeskrift for Laeger 169(9): 789-791, 2007

A randomised, double-blind, placebo-controlled, pan-European study of a recombinant humanised antibody to alpha4 integrin in moderate to severely active Crohns disease. Gastroenterology 120(5 Supplement 1): A 127-A 128, April, 2001

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. New England Journal of Medicine 352(24): 2499-2507, 2005

Effective treatment of mouse experimental colitis by alpha 2 integrin antibody: comparison with alpha 4 antibody and conventional therapy. Acta Physiologica 207(2): 326-336, 2013

Antibody to alpha4beta7 integrin for ulcerative colitis. New England Journal of Medicine 353(11): 1180-1; Author Reply 1180-1, 2005

Treatment of ulcerative colitis with an engineered human anti-TNF-alpha antibody CDP571. Gastroenterology 110(4 SUPPL ): A905, 1996

Recombinant alpha-2b-interferon treatment in a patient with chronic C concomitant hepatitis and outbreak of ulcerative colitis. Revista Espanola de Enfermedades Digestivas 89(5): 399-401, 1997

Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha. Gut 40(5): 628-633, 1997

Treatment of ulcerative colitis in the cottontop tamarin using anti-tumour necrosis factor alpha antibody. Gastroenterology 106(4 SUPPL ): A792, 1994

Humanized antibody to the alpha4beta7 integrin for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews (): Cd007571-Cd007571, 2009

AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human Trial. Journal of Crohn's & Colitis 10(6): 631-640, 2016

Method of treating ulcerative colitis or crohns disease by administering an antibody toalphaEbeta7 integrin. Official Gazette of the United States Patent & Trademark Office Patents 1262(4), Sep 24, 2002